Quantum Biopharma Reports Strong Third Quarter Results Maintaining 'No Going Concern' Status with Cash Runway Extending Beyond March 2027, and $572,000 USD Gains in Crypto Portfolio

Executive Summary

• Q3 2025 financials show a 275% increase in shareholder equity to US$7.5 M and an 87% reduction in the debt‑to‑equity ratio to 0.89×, driven by elimination of convertible debenture liabilities.
• Digital asset portfolio (primarily Bitcoin) generated realized gains of US$572 k; total crypto holdings now valued at US$5.2 M.
• Clinical progress on Lucid‑21‑302 (Lucid‑MS): Phase 1 oral toxicity studies completed with no safety signals, first MS patient scanned in joint PET study with MGH, and IND preparation agreement signed for FDA filing.

Key Details

• Balance Sheet Improvements – Total liabilities fell from US$13.2 M to US$6.6 M; current ratio improved from 0.78× to 1.41×; equity‑to‑total‑assets rose from 13% to 53%.
• Liquidity Outlook – Management states cash on hand is sufficient to fund operations beyond March 2027.
• Digital Assets – Crypto portfolio valued at US$5.2 M (up from US$0.8 M Dec 31 2024); realized gains of US$572 k recorded in Q3.
• Lucid‑MS Program – Phase 1 oral toxicity studies (3‑month & 6‑month) completed with no adverse effects; oral formulation selected for upcoming Phase 2 efficacy trial.
• Partnerships & Agreements –
• Contract manufacturing agreement signed with a leading CDMO to produce oral Lucid‑MS formulation.
• Joint PET imaging study with Massachusetts General Hospital initiated; first MS patient scanned.
• IND preparation services agreement executed with a global CRO for FDA submission.
• Unbuzzd Wellness Capital Raise – Licensee launched a Reg D 506(c) offering to raise up to US$5 M for growth and potential IPO; the financing is non‑dilutive to Quantum’s equity stake.
• Health Canada Product License – Granted PN 80144141 for “Qlarity” (energy & metabolism supplement), permitting sales in Canada.
• Legal Update – Filed memorandum of law opposing CIBC World Markets and RBC Dominion Securities’ joint motion to dismiss the lawsuit alleging stock‑market manipulation; case pending.
• Special Dividend – Record date October 27 2025; CVR (contingent value rights) distributed on a one‑for‑one basis to Class B Subordinate Voting Shareholders.
• Warrants – All warrants held by hedge funds have expired post‑Q3.

Notable Quotes

“We have finished the third quarter of 2025 in a stronger position than at close of Q2 2025… our balance sheet is robust, and we are advancing multiple near‑term monetization events.” – Donal Carroll, CFO

“Our MS program is making significant strides; the first patient has undergone PET scanning, and Phase 1 toxicity data confirm safety, positioning us for a Phase 2 trial.” – Donal Carroll, CFO